PROCEPT BioRobotics Corporation $PRCT Shares Acquired by Advisors Asset Management Inc.

Advisors Asset Management Inc. grew its position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 14.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,464 shares of the company’s stock after buying an additional 3,455 shares during the period. Advisors Asset Management Inc.’s holdings in PROCEPT BioRobotics were worth $1,582,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in PRCT. CWM LLC boosted its stake in shares of PROCEPT BioRobotics by 40.7% during the 2nd quarter. CWM LLC now owns 1,228 shares of the company’s stock worth $71,000 after acquiring an additional 355 shares in the last quarter. Assetmark Inc. increased its stake in PROCEPT BioRobotics by 5.1% in the second quarter. Assetmark Inc. now owns 8,333 shares of the company’s stock valued at $480,000 after acquiring an additional 407 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in PROCEPT BioRobotics by 7.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,426 shares of the company’s stock worth $543,000 after buying an additional 647 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of PROCEPT BioRobotics in the first quarter valued at about $40,000. Finally, Ameritas Investment Partners Inc. raised its position in PROCEPT BioRobotics by 15.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,364 shares of the company’s stock worth $309,000 after purchasing an additional 703 shares during the last quarter. Institutional investors own 89.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on PRCT shares. Leerink Partners reaffirmed an “outperform” rating and issued a $55.00 target price on shares of PROCEPT BioRobotics in a research note on Wednesday, November 5th. Oppenheimer upgraded shares of PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 target price for the company in a report on Tuesday, September 2nd. BTIG Research reissued a “neutral” rating on shares of PROCEPT BioRobotics in a research note on Tuesday, September 16th. Wells Fargo & Company cut their price objective on PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Finally, Piper Sandler reissued an “overweight” rating and issued a $50.00 price target (down from $55.00) on shares of PROCEPT BioRobotics in a report on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $59.78.

PROCEPT BioRobotics Stock Performance

Shares of PRCT opened at $31.68 on Friday. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -20.70 and a beta of 0.98. PROCEPT BioRobotics Corporation has a 12 month low of $27.80 and a 12 month high of $99.60. The company has a current ratio of 8.44, a quick ratio of 7.20 and a debt-to-equity ratio of 0.14. The stock has a 50 day moving average of $33.52 and a 200 day moving average of $45.13.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.03. The company had revenue of $83.33 million during the quarter, compared to analysts’ expectations of $80.78 million. PROCEPT BioRobotics had a negative return on equity of 21.72% and a negative net margin of 28.20%.The firm’s quarterly revenue was up 42.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.40) earnings per share. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts forecast that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).